Effect of doxorubicin treatment at the expression levels of BCL-2 and BAX on MCF7 cell line | ||||
| The Arab Journal of Scientific Research | ||||
| Article 2, Volume 2, Issue 2, 2018, Page 5-9 PDF (1.15 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ajsr.2018.171727 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mohammed H. Awwad1; Hayam ELSharawy2; Fatma Ashour2 | ||||
| 1Department of Zoology, Faculty of Science, University of Benha, Benha, Egypt. | ||||
| 2Department of Zoology, Faculty of Science, University of Benha, Benha, | ||||
| Abstract | ||||
| Breast cancer (BC) is a chemotherapy sensitive tumor. Doxorubicin hydrochloride (DOX) is one of the most common chemotherapeutic drugs that used in breast cancer treatment. It intercalates with DNA and stops the replication process. And it was found that, following 48h of DOX treatment, cell death Increases in ER+ breast cancer cell lines. Here we investigated the effect of DOX treatment at the antiapoptotic BCL-2 and the proapoptotic BAX genes. Methods: MCF7 cell line was cultured in the appropriate media and treated with DOX for 48 hours. Then the expression levels of BCL-2 and BAX were investigated using qPCR. Results: the expression of BCL-2 showed a slight increase in its levels after treatment while BAX gene showed a striking increase (3.62 fold). Conclusion: our results was in line with previous studies showed that treatment with DOX induce apoptosis in MCF7 cells. | ||||
| References | ||||
|
Bateman, A. C. and E. C. Shaw (2013). "Breast pathology." Surgery (Oxford) 31(1): 4-10.
Dole, M. G., R. Jasty, M. J. Cooper, C. B. Thompson, G. Nuñez and V. P. Castle (1995). "Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis." Cancer research 55(12): 2576-2582.
Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin (2010). "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008." International journal of cancer 127(12): 2893-2917.
Lacroix, M. and G. Leclercq (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update." Breast cancer research and treatment 83(3): 249-289.
Leung, L. K. and T. T. Wang (1999). "Differential effects of chemotherapeutic agents on the Bcl‐2/Bax apoptosis pathway in human breast cancer cell line MCF‐7." Breast cancer research and treatment 55(1): 73-83.
Lippman, M. E. and R. B. DICKSON'r (2013). Mechanisms of growth control in normal and malignant breast epithelium. Recent Progress in Hormone Research: Proceedings of the 1988 Laurentian Hormone Conference, Academic Press.
Lüpertz, R., W. Wätjen, R. Kahl and Y. Chovolou (2010). "Dose-and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells." Toxicology 271(3): 115-121.
Mcgahon, A. J., A. P. Costa Pereira, L. Daly and T. G. Cotter (1998). "Chemotherapeutic drug‐induced apoptosis in human leukaemic cells is independent of the Fas (APO‐1/CD95) receptor/ligand system." British journal of haematology 101(3): 539-547 . Minn, A. J., C. M. Rudin, L. H. Boise and C. B. Thompson (1995). "Expression of bcl-xL can confer a multidrug resistance phenotype." Blood 86(5): 1903-1910.
Nazário, A. C. P., G. Facina and J. R. Filassi (2015). "Breast cancer: news in diagnosis and treatment." Revista da Associação Médica Brasileira 61(6): 543-552.
Pritchard, J. E., P. M. Dillon, M. R. Conaway, C. M. Silva and S. J. Parsons (2012). "A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model." Oncology 83(6): 305-320.
Puhalla, S., S. Bhattacharya and N. E. Davidson (2012). "Hormonal therapy in breast cancer: a model disease for the personalization of cancer care." Molecular oncology 6(2): 222-236.
Rusetskaya, N., N. Y. Lukyanova and V. Chekhun (2009). "Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin." Exp Oncol 31: 140-143.
Sharifi, S., J. Barar, M. S. Hejazi and N. Samadi (2015). "Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells." Advanced pharmaceutical bulletin 5(3): 351.
Sharma, G., A. K. Tyagi, R. P. Singh, D. C. Chan and R. Agarwal (2004). "Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells." Breast cancer research and treatment 85(1): 1-12.
Sotiriou, C., S.-Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. B. Fox, A. L. Harris and E. T. Liu (2003). "Breast cancer classification and prognosis based on gene expression profiles from a population-based study." Proceedings of the National Academy of Sciences 100(18): 10393-10398.
Teixeira, C., J. C. Reed and M. C. Pratt (1995). "Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells." Cancer research 55(17): 3902-3907. | ||||
|
Statistics Article View: 132 PDF Download: 139 |
||||
